Target intelligence / Profile preview

Gram-negative bacterial peptidoglycan (PGN)

Target
PGN
Molecular classification
Other
01

Overview

Gram-negative bacterial peptidoglycan is a vital structural polymer located within the periplasmic space, situated between the inner cytoplasmic membrane and the outer membrane. It is composed of alternating residues of N-acetylglucosamine and N-acetylmuramic acid, which are cross-linked by pentapeptide side chains to form a resilient, mesh-like layer (Vollmer et al., 2008). The primary biological role of this molecule is to maintain cell shape and provide the mechanical strength necessary to withstand high internal osmotic pressure, thereby preventing bacterial lysis (Silhavy et al., 2010). During bacterial growth and division, the peptidoglycan layer undergoes constant remodeling, a process that is highly regulated by various enzymes. In the context of infectious disease, peptidoglycan serves as a major pathogen-associated molecular pattern (PAMP); specifically, its breakdown products (muropeptides) are recognized by host intracellular receptors like NOD1 to initiate an immune response (Girardin et al., 2003). Because peptidoglycan is unique to prokaryotes, it is the primary target for several classes of antibiotics, most notably the beta-lactams, which inhibit the transpeptidation enzymes required for its synthesis (Kohanski et al., 2010). Therapeutic challenges include the presence of the Gram-negative outer membrane, which acts as a permeability barrier, and the rapid evolution of resistance mechanisms such as beta-lactamases that degrade drugs targeting this structure.

Other names
MureinPeptidoglycan layerBacterial cell wall polymerPG
02

Mechanism of action

Inhibition of peptidoglycan biosynthesis and cross-linking by targeting enzymes such as penicillin-binding proteins (PBPs) or Mur ligases.

03

Biological functions

Structural integrityOsmotic protectionCell shape maintenanceCell division scaffoldImmune response
04

Disease associations

InfectionInflammationSepsis
05

Safety considerations

Antibiotic resistanceJarisch-Herxheimer reactionHypersensitivity reactionsGastrointestinal dysbiosis
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Soluble muropeptidesNOD1 activation levelsPeptidoglycan-recognition proteins (PGRPs)

Beyond the preview

Go deeper on Gram-negative bacterial peptidoglycan (PGN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gram-negative bacterial peptidoglycan (PGN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call